title: DREADD: a chemogenetic GPCR signaling platform.
abstract: Recently, we created a family of engineered G protein-coupled receptors (GPCRs) called DREADD (designer receptors exclusively activated by designer drugs) which can precisely control three major GPCR signaling pathways (Gq, Gi, and Gs). DREADD technology has been successfully applied in a variety of in vivo studies to control GPCR signaling, and here we describe recent advances of DREADD technology and discuss its potential application in drug discovery, gene therapy, and tissue engineering.
authors.affiliation: Department of Pharmacology, University of North Carolina Chapel Hill Medical School, Chapel Hill, NC (Drs Zhu and Roth).
authors.forename: Hu
authors.initials: H
authors.lastname: Zhu
authors.affiliation: Department of Pharmacology, University of North Carolina Chapel Hill Medical School, Chapel Hill, NC (Drs Zhu and Roth). bryan_roth@med.unc.edu.
authors.forename: Bryan L
authors.initials: BL
authors.lastname: Roth
mesh_terms: D000818:Animals; D005821:Genetic Techniques; D006801:Humans; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D043562:Receptors, G-Protein-Coupled / Q000235:genetics* / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology
chemical_list: D043562:Receptors, G-Protein-Coupled
keywords: GPCRs; GsD; chemogenetics; hM3Dq; hM4Di